In vitro bactericidal activity of antimicrobial agents against enterohaemorrhagic Escherichia coli

Journal of Antimicrobial Chemotherapy

Volumn 54, Issue 5, 2004, Pages 897-903

  Oie, Shigeharu ^a   Ishitobi, Junko ^a   Sawa, Akihiro ^b   Tomita, Masaaki ^c   Kamiya, Akira ^a  

^a YAMAGUCHI UNIVERSITY HOSPITAL   (Japan)

^b HIROSHIMA INTERNATIONAL UNIVERSITY   (Japan)

^c Yamaguchi Prefectural Research Institute of Public Health   (Japan)

Author keywords

Cefoperazone; Fosfomycin; Kanamycin; Killing kinetics; Norfloxacin

Indexed keywords

ANTIINFECTIVE AGENT; BACTERIAL DNA; CEFOPERAZONE; FOSFOMYCIN; KANAMYCIN; NORFLOXACIN;

ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DNA DETERMINATION; ENTEROBACTER INFECTION; ESCHERICHIA COLI; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PULSED FIELD GEL ELECTROPHORESIS; STRAIN DIFFERENCE;

ANTI-BACTERIAL AGENTS; CEFOPERAZONE; ELECTROPHORESIS, GEL, PULSED-FIELD; ESCHERICHIA COLI O157; FOSFOMYCIN; KANAMYCIN; MICROBIAL SENSITIVITY TESTS; NORFLOXACIN;

EID: 8844239126     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh442     Document Type: Article

References (30)

1. Mølbak, K., Mead, P. S., Griffin, P. M. et al. (2002). Antimicrobial therapy in patients with Escherichia coli O157:H7 infection. Journal of the American Medical Association 288, 1014-6.
2. Sadfar, N., Said, A., Gangnon, R. E. et al. (2002). Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O15:H7 enteritis. Journal of the American Medical Association 288, 996-1001.
3. Boyce, T. G., Swerdlow, D. L. & Griffin, P. M. (1995). Escherichia coli O157:H7 and the hemolytic-uremic syndrome. New England Journal of Medicine 333, 364-8.
4. Karmali, M. A., Petric, M., Lim, C. et al. (1985). The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. Journal of Infectious Diseases 151, 775-82.
5. Ostroff, S. M., Kobayashi, J. M. & Lewis, J. H. (1989). Infections with Escherichia coli O157:H7 in Washington state. Journal of the American Medical Association 262, 355-9.
6. Cimolai, N., Anderson, J. & Morrison, B. J. (1989). Antibiotics for Escherichia coli O157:H7 enteritis? Journal of Antimicrobial Chemotherapy 23, 807-8.
7. Robson, W. L. M., Scott, R. B. & Fick, G. H. (1990). Influence of antidiarrheal and antimicrobial medications on the hemorrhagic colitis associated with hemolytic-uremic syndrome. Journal of Pediatrics 117, 675-6.
8. Proulx, F., Turgeon, J. P., Delage, G. et al. (1992). Randomized, controlled trial of antibiotic therapy for Escherichia coli O157:H7 enteritis. Journal of Pediatrics 121, 299-303.
9. Cimolai, N., Carter, J. E., Morrison, B. J. et al. (1990). Risk factors for the progression of Escherichia coli O157:H7 enteritis to hemolytic-uremic syndrome. Journal of Pediatrics 116, 589-92.
10. Ikeda, K., Kimoto, K., Takatorige, T. et al. (1999). Effect of early fosfomycin treatment on prevention of hemolytic uremic syndrome accompanying Escherichia coli O157:H7 infection. Clinical Nephrology 52, 357-62.
11. Shiomi, M., Togawa, M., Fujita, K. et al. (1999). Effect of early oral fluoroquinolones in hemorrhagic colitis due to Escherichia coli O157:H7. Pediatrics International 41, 228-32.
12. Yoshimura, K., Fujii, J., Taniguchi, H. et al. (1999). Chemotherapy for enterohemorrhagic Escherichia coli O157:H infection in a mouse model. Immunology and Medical Microbiology 26, 101-8.
13. Isogai, E., Isogai, H., Hayashi, S. et al. (2000). Effect of antibiotics, levofloxacin and fosfomycin on a mouse model with Escherichia coli O157 infection. Microbiology and Immunology 44, 89-95.
14. Yoh, M., Frimpong, E. K., Voravuthikunchai, S. P. et al. (1999). Effect of subinhibitory concentrations of antimicrobial agents (quinolones and macrolide) on the production of verotoxin by enterohemorrhagic Escherichia coli O157:H7. Canadian Journal of Microbiology 45, 732 -9.
15. Higami, S., Nishimoto, K., Kawamura, T. et al. (1997). Retrospective analysis of the relationship between HUS incidence and antibiotics among patients with Escherichia coli O157 enterocolitis in the Sakai outbreak. Kansenshogaku Zasshi 72, 266-72.
16. Swerdlow, D. L., Woodruff, B. A., Brady, R. C. et al. (1992). A waterborne outbreak in Missouri of Escherichia coli O157:H7 associated with bloody diarrhea and death. Annals of Internal Medicine 117, 812-9.
17. Oie, S., Kamiya, A., Tomita, M. et al. (1997). In vitro susceptibility of Escherichia coli O157 to several antimicrobial agents. Biological and Pharmaceutical Bulletin 20 584-5.
18. Tsuboi, I., Ida, H., Yoshikawa, E. et al. (1998). Antibiotic susceptibility of enterohemorrhagic Escherichia coli O157:H7 isolated from an outbreak in Japan in 1996. Antimicrobial Agents and Chemotherapy 42, 431-2.
19. Stock, I. & Wiedemann, B. (1999). Natural antibiotic susceptibility of Escherichia coli, Shigella, E. vulneris, and E. hermannii strains. Diagnostic Microbiology and Infectious Disease 33, 187-99.
20. Meng, J., Zhao, S., Doyle, M. P. et al. (1998). Antibiotic resistance of Escherichia coli O157:H7 and O157:NM isolated from animals, food, and humans. Journal of Food Protection 61, 1511-4.
21. Sawamura, S., Tanaka, K. & Koga, Y. (1999). Therapeutic effects of antibiotics against enterohemorrhagic Escherichia coli (EHEC) O157:H7 (O157) infection: In vitro analysis using germfree mice. Kansenshogaku Zasshi 73, 1054-63.
22. Oie, S., Kawakami, M., Kamiya, A. et al. (2002). In vitro susceptibility of four serotypes of enterohaemorrhagic Escherichia coli to antimicrobial agents. Biological & Pharmaceutical Bulletin 25, 671-3.
23. Fukushima, H., Hashizume, T., Morita, Y. et al. (1999). Clinical experiences in Sakai city hospital during the massive outbreak of enterohemorrhagic Escherichia coli O157 infections in Sakai city, 1996. Pediatrics International 41, 213-7.
24. Barry, A. L. & Fuchs, P. C. (1991). In vitro susceptibility testing procedures for fosfomycin tromethamine. Antimicrobial Agents and Chemotherapy 35, 1235-8.
25. Shetty, N., Srinivasan, S., Holton, J. et al. (1999). Evaluation of microbicidal activity of a new disinfectant: Sterilox® 2500 against Clostridium difficile spores, Helicobacter pylori vancomycin resistant Enterococcus species, Candida albicans and several Mycobacterium species. Journal of Hospital Infection 41, 101-5.
26. Murray, B. E., Singh, K. V., Markowitz, S. M. et al. (1991). Evidence for clonall spread of a single strain of β-lactamase-producing Enterococcus (Streptococcus) faecalis to six hospitals in five states. Journal of Infectious Diseases 163, 780-5.
27. Cofsky, R. D., Bouchet, L. & Landesman, S. H. (1984). Recovery of norfloxacin in faeces after administration of a single oral dose to human volunteers. Antimicrobial Agents and Chemotherapy 26, 110-1.
28. Nakamura, T., Hashimoto, I., Sawada, Y. et al. (1980). Cefoperazone concentrations in bile and gall bladder wall after intravenous administration. Antimicrobial Agents and Chemotherapy 18, 980-2.
29. Hewitt, W. L. & Finegold, S. M. (1958). Laboratory studies with kanamycin. Annals of the New York Academy of Sciences 76 122-8.
30. Kou, E. & Yamazaki, S. (2000). Fecal fosfomycin concentrations in intestinal infection in children. Japanese Journal of Pediatrics 53, 1519.